乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Meeting Coverage >

GICS

<乌鸦传媒>Immunotherapy Not Additive to Standard of Care for Untreated Metastatic CRC

No difference in survival outcomes with add-on nivolumab to chemo, bevacizumab

<乌鸦传媒>Potential New First-Line Options for Unresectable Hepatocellular Carcinoma

Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib

<乌鸦传媒>Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers

Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer

<乌鸦传媒>More Data for Upfront PD-1 Inhibition in Gastric, Esophageal Cancer

Updates from two landmark trials show consistent benefits across subgroups, PD-L1 expression

<乌鸦传媒>Preop RT Flunks Test in Borderline Pancreatic Cancer

Chemotherapy alone judged efficacious but not chemoradiation

<乌鸦传媒>Drug Hits Target in Advanced Biliary Cancer

Responses in up to a third of patients with FGFR inhibitor infigratinib

<乌鸦传媒>Liquid Biopsy Predicts Colon Cancer Relapse Months Before CT

Test for ctDNA outperformed existing biomarker, may help guide therapy

<乌鸦传媒>New Target to Attack in Stomach Cancer

PFS, OS improved with fibroblast growth factor receptor inhibitor in non-HER2 disease

<乌鸦传媒>Doublet for BRAF-Mutant Colon Cancer Heads to FDA

No need for triplet, encorafenib plus cetuximab matches OS in updated analysis

<乌鸦传媒>High Response Rate in HER2+ Esophagogastric Cancer

Summary findings from the Gastrointestinal Cancers Symposium

<乌鸦传媒>Death Risk Rises With No Colonoscopy After Stage I CRC

Three-fold increase, but is colonoscopy the driver?

<乌鸦传媒>Mixed Results with Immune Tx in Advanced, Refractory Colon Ca

Overall survival gains were modest to none in different stages of CRC

<乌鸦传媒>Metastatic Gastric Ca Treatments Show Mixed Results

FTD/TPI effective, but mFOLFOX plus biologic didn't improve survival

<乌鸦传媒>'Incredibly Impressive' Activity in Biliary Ca with Combo Tx

Responses in about 40% of patients with BRAF/MEK inhibitor pairing

<乌鸦传媒>Combo Therapy Doubles PFS in Unresectable HCC

Chemoembolization plus sorafenib tops embolization alone

<乌鸦传媒>Immunotherapy Combo Active in High-Risk CRC

Disease control in 80% with nivolumab-ipilimumab

<乌鸦传媒>Extensive Lavage No Help in Gastric Cancer

Survival outcomes not improved with intraperitoneal treatment

<乌鸦传媒>Small PFS Bump in Gastric/GEJ Cancer

Clinical vs statistical significance in trial of first-line ramucirumab

<乌鸦传媒>QoL Benefits with Palliative Surgery for Gastric Cancer

Solid food intake facilitated, anxiety and pain decreased

<乌鸦传媒>Nivolumab Slows Advanced Gastric Cancer

Significant reduction in hazards for survival, PFS in pretreated patients

<乌鸦传媒>PET-Guided Therapy Switch for Esophageal Cancer

Improved response with switch from ineffective treatment

<乌鸦传媒>Exercise May Extend Survival in Metastatic Colon Cancer

Progression, survival hazards improved with moderate activitiy

<乌鸦传媒>Shorter Therapy an Option for High-Risk Anal Cancer

Abbrieviated chemoradiation matches standard with less toxicity

<乌鸦传媒>CRC Regimens Give Survival Bump in Second Line

Ramucirumab trial meets primary endpoint; famitinib offers respectable disease control rate.

<乌鸦传媒>More Drugs, Better Survival in Metastatic Colon Cancer

Addition of oxaliplatin to FOLFIRI and bevacizumab doubled 5-year survival.

<乌鸦传媒>Combo Active in Neuroendocrine Cancers

SAN FRANCISCO -- More than 90% of patients with neuroendocrine tumors had objective responses or stable disease when treated with an off-the-shelf chemotherapy doublet, results of a small study showed.

<乌鸦传媒>Surgery Boosts Outcomes in Esophageal Cancer

SAN FRANCISCO -- Surgery after chemoradiotherapy increased overall and disease-free survival compared with chemoradiotherapy alone in advanced esophageal cancer treatment, researchers reported here.

<乌鸦传媒>ER Presentation Not the End for Colon Cancer Patients

SAN FRANCISCO -- Curative therapy is still a possibility, even if a colon cancer patient is seen for the first time in the emergency department with acute symptoms, researchers said here.

<乌鸦传媒>Gastric Ca Survival Rates Down, Chemo Use Up

SAN FRANCISCO -- A decline in survival rates in stage IV gastric cancer coincides with the increased use of chemotherapy rather than radiation and surgery, researchers found.